Pregabalin Capsule
Product Images NDC 71335-1745

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351745)

The image shows a drug packaging label for Pregabalin 150 mg capsules by Bryant Ranch Prepack. It states the product is a human prescription drug, capsules for oral use. The label compares it to Lyrica 150 mg capsules and indicates the NDC code 71335-1745. Storage instructions and safety warnings are also visible.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for estimating creatinine clearance (CLCr) is shown. It calculates CLCr based on age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients. The formula is presented as a mathematical equation.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph titled 'Study E1 and Study E3' showing responder rates (%) on the vertical axis and different dosages of Pregabalin and placebo on the horizontal axis. Study E1 includes placebo and doses from 50 mg/day to 600 mg/day with BID administration; Study E3 includes placebo, 600 mg/day BID, and 600 mg/day TID. Responder rates increase with higher dosages. Sample sizes (N) are shown below each bar. A note indicates statistically significant differences versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percent change from baseline against pregabalin dose (mg/day). Data are from three studies (E1, E2, E3) with different dosing schedules (BID and TID). The graph shows increasing seizure reduction with higher doses, with statistically significant p-values indicated.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin dosed at 200 mg three times a day, 150 mg three times a day, 75 mg three times a day, and placebo, illustrating patient improvement trends over a range of pain improvement percentages.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing percent improvement from baseline to Week 12 BOCF for Pregabalin versus placebo. The x-axis represents percent improvement, and the y-axis shows the percentage of subjects improved. The solid line represents Pregabalin, showing higher improvement percentages compared to the dashed line for placebo.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percentage of subjects improved from baseline to week 16 based on the Brief Pain Inventory-Short Form (BPI-SF) for Pregabalin versus placebo. The x-axis represents percent improvement intervals from 0 to 100, while the y-axis shows the percentage of subjects improved, with two lines illustrating outcomes for Pregabalin (solid line) and placebo (dashed line).*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The y-axis shows the percent of patients improved, and the x-axis shows percent improvement in pain, with two vertical reference lines marked around 37% and 50% improvement.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares pregabalin 75 mg, 150 mg, and 300 mg taken twice a day against placebo, showing varying levels of patient improvement.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved, with comparison among the three treatment groups.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph displaying the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Pregabalin groups show higher percentages of patients improved compared to placebo across various levels of pain improvement.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. It compares Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg with placebo, illustrating differences in patient response at varying levels of pain improvement.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days between Pregabalin and Placebo groups. The vertical axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the horizontal axis represents days. The Pregabalin group shows a higher percentage of subjects without LTR over time compared to the Placebo group.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of Pregabalin, a prescription drug active ingredient. The structure shows the molecular arrangement including an amino group (NH2) and a carboxyl group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.